OptiNose, Inc. (OPTN): Price and Financial Metrics
GET POWR RATINGS... FREE!
OPTN POWR Grades
- OPTN scores best on the Sentiment dimension, with a Sentiment rank ahead of 86.12% of US stocks.
- OPTN's strongest trending metric is Momentum; it's been moving up over the last 179 days.
- OPTN ranks lowest in Momentum; there it ranks in the 32nd percentile.
OPTN Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for OPTN is -1.35 -- better than merely 4.65% of US stocks.
- OPTN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.39% of US stocks.
- In terms of volatility of its share price, OPTN is more volatile than 87.92% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to OPTINOSE INC, a group of peers worth examining would be LPRO, TELA, PWFL, CLIR, and BON.
- Visit OPTN's SEC page to see the company's official filings. To visit the company's web site, go to www.optinose.com.
OPTN Valuation Summary
- In comparison to the median Healthcare stock, OPTN's price/sales ratio is 31.58% higher, now standing at 2.5.
- Over the past 66 months, OPTN's EV/EBIT ratio has gone down 28.8.
Below are key valuation metrics over time for OPTN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| OPTN | 2023-03-17 | 2.5 | -3.4 | -2.6 | -3.9 |
| OPTN | 2023-03-16 | 2.7 | -3.6 | -2.7 | -4.1 |
| OPTN | 2023-03-15 | 2.7 | -3.6 | -2.7 | -4.1 |
| OPTN | 2023-03-14 | 2.6 | -3.5 | -2.7 | -4.0 |
| OPTN | 2023-03-13 | 2.6 | -3.5 | -2.6 | -4.0 |
| OPTN | 2023-03-10 | 2.5 | -3.4 | -2.6 | -3.9 |
OPTN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- OPTN has a Quality Grade of C, ranking ahead of 30.77% of graded US stocks.
- OPTN's asset turnover comes in at 0.372 -- ranking 127th of 682 Pharmaceutical Products stocks.
- ALT, FOLD, and RDUS are the stocks whose asset turnover ratios are most correlated with OPTN.
The table below shows OPTN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.372 | 0.861 | -0.687 |
| 2021-03-31 | 0.317 | 0.854 | -0.758 |
| 2020-12-31 | 0.282 | 0.847 | -0.844 |
| 2020-09-30 | 0.258 | 0.832 | -0.995 |
| 2020-06-30 | 0.251 | 0.840 | -1.196 |
| 2020-03-31 | 0.225 | 0.841 | -1.335 |
OPTN Price Target
For more insight on analysts targets of OPTN, see our OPTN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.00 | Average Broker Recommendation | 1.4 (Strong Buy) |
OPTN Stock Price Chart Interactive Chart >
OPTN Price/Volume Stats
| Current price | $1.84 | 52-week high | $4.30 |
| Prev. close | $1.68 | 52-week low | $1.55 |
| Day low | $1.68 | Volume | 93,100 |
| Day high | $1.84 | Avg. volume | 156,872 |
| 50-day MA | $1.75 | Dividend yield | N/A |
| 200-day MA | $2.72 | Market Cap | 205.73M |
OptiNose, Inc. (OPTN) Company Bio
OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. The company was founded in 2010 and is based in Yardley, Pennsylvania.
Latest OPTN News From Around the Web
Below are the latest news stories about OPTINOSE INC that investors may wish to consider to help them evaluate OPTN as an investment opportunity.
OptiNose, Inc. (NASDAQ:OPTN) Q4 2022 Earnings Call TranscriptOptiNose, Inc. (NASDAQ:OPTN) Q4 2022 Earnings Call Transcript March 7, 2023 Operator: Good day and thank you for standing by. Welcome to the OptiNose’s Fourth Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. . Please be advised that today’s […] |
We're Not Very Worried About OptiNose's (NASDAQ:OPTN) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
Q4 2022 OptiNose Inc Earnings CallQ4 2022 OptiNose Inc Earnings Call |
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue EstimatesOptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational HighlightsCompany reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal polyps indication and there is no FDA-approved medication for these patients Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical |
OPTN Price Returns
| 1-mo | 6.36% |
| 3-mo | N/A |
| 6-mo | -47.58% |
| 1-year | -30.04% |
| 3-year | -55.77% |
| 5-year | -90.98% |
| YTD | -0.54% |
| 2022 | 14.20% |
| 2021 | -60.87% |
| 2020 | -55.10% |
| 2019 | 48.71% |
| 2018 | -67.20% |
Continue Researching OPTN
Here are a few links from around the web to help you further your research on OptiNose Inc's stock as an investment opportunity:OptiNose Inc (OPTN) Stock Price | Nasdaq
OptiNose Inc (OPTN) Stock Quote, History and News - Yahoo Finance
OptiNose Inc (OPTN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...